Does CERITINIB Cause Second primary malignancy? 15 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Second primary malignancy have been filed in association with CERITINIB (ZYKADIA). This represents 0.5% of all adverse event reports for CERITINIB.
15
Reports of Second primary malignancy with CERITINIB
0.5%
of all CERITINIB reports
3
Deaths
5
Hospitalizations
How Dangerous Is Second primary malignancy From CERITINIB?
Of the 15 reports, 3 (20.0%) resulted in death, 5 (33.3%) required hospitalization, and 1 (6.7%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CERITINIB. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does CERITINIB Cause?
Malignant neoplasm progression (523)
Diarrhoea (452)
Death (391)
Nausea (381)
Vomiting (270)
Metastases to central nervous system (203)
Non-small cell lung cancer (183)
Fatigue (149)
Decreased appetite (139)
Dyspnoea (137)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which CERITINIB Alternatives Have Lower Second primary malignancy Risk?
CERITINIB vs CERLIPONASE ALFA
CERITINIB vs CERTICAN
CERITINIB vs CERTOLIZUMAB
CERITINIB vs CERTOLIZUMAB PEGOL
CERITINIB vs CERTOPARIN